| Bioactivity | RCM-1 is a forkhead box M1 (FOXM1) inhibitor with an EC50 of 0.72 μM in U2OS cells. RCM-1 blocks the nuclear localization and increased the proteasomal degradation of FOXM1. RCM-1 can be used for asthma and other chronic airway diseases research[1]. | ||||||||||||
| Target | FOXM1. | ||||||||||||
| Invitro | RCM-1 blocks the nuclear localization and increased the proteasomal degradation of FOXM1, a transcription factor critical for the differentiation of goblet cells from airway progenitor cells. In cultured airway epithelial cells, RCM-1 reduces IL-13 and STAT6 signaling and prevented the expression of the STAT6 target genes Spdef and Foxa3, which are key transcriptional regulators of goblet cell differentiation[1]. | ||||||||||||
| In Vivo | RCM-1 reduces airway resistance, increased lung compliance, and decreased proinflammatory cytokine production in mice exposed to the house dust mite and interleukin-13 (IL-13), which triggers goblet cell metaplasia. In mice, RCM-1 reduces IL-13 and STAT6 signaling and prevented the expression of the STAT6 target genes Spdef and Foxa3[1]. | ||||||||||||
| Name | RCM-1 | ||||||||||||
| CAS | 339163-65-4 | ||||||||||||
| Formula | C20H12N2OS4 | ||||||||||||
| Molar Mass | 424.58 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Lifeng Sun, et al. The FOXM1 inhibitor RCM-1 suppresses goblet cell metaplasia and prevents IL-13 and STAT6 signaling in allergen-exposed mice. Sci Signal. 2017 Apr 18;10(475):eaai8583. |